anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the preparation method of a diclazuril micro-emulsion. The preparation procedure of the diclazuril micro-emulsion is as follows: (1) florfenicol is weighed, added with tween-80 and is mixed uniformly; (2) propanediol is added and mixed uniformly; (3) DMF dimethylformamide is added and mixed uniformly; (4) water is added and mixed, and then florfenicol micro-emulsion is prepared. The invention adopts advanced microemulsion technology, and florfenicol which is slightly soluble in water is prepared into florfenicol micro-emulsion solution in any proportion. The preparation method effectively improves the bioavailability of the product, the property of the quality is stationary and the absorption is complete. The drug is released by targeting drug release and the product has the characteristics of rapid, durable and high effects. The half-life is long and the effective plasma concentration is maintained in bodies for a long time. The diclazuril micro-emulsion of the invention has low toxicity, high effects, sound safety, is capable of curing bacterial diseases, is drinkable with water and the use is convenient.
ILD is a common complication of CTD, with high disability rate and fatality rate, poor prognosis and high fatality rate. Ild is one of the main causes threatening the life of patients. The objective of this study was to evaluate the efficacy and safety of Qifangfeixian granules in the treatment of CTD-ILD patients, and to provide a new treatment plan for CTD-ILD patients. This is a randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Qifangfeixian granules in the treatment of patients with fibrotic interstitial lung disease. The study drugs included Qifangfeixian Granule and placebo, which was identical in appearance, taste and weight with Qifangfeixian Granule, and were given 1 bag twice a day. This study planned to enroll 124 subjects, who were randomly assigned at a ratio of 1:1, with 62 subjects in each group. Subjects who met all the inclusion criteria and did not meet the exclusion criteria at baseline were randomly assigned to either of the following two groups: (1) Qifangfeixian Granule treatment group: orally administered with 1 bag of Qifangfeixian granule twice a day; (2) Placebo (PRO) control group: orally administered with 1 bag of placebo twice a day. If participants withdraw from the study early, they will be followed up for 4 weeks. Participants were allowed to make dose adjustments during treatment and were withdrawn from the study when a serious adverse event occurred or medication was discontinued due to an adverse event. Throughout the course of the study, safety checks and assessments will be conducted according to the time points specified in the protocol, including adverse events, HRCT, clinical laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function, myocardial enzymes, etc.), 12-lead electrocardiogram, vital signs, and physical examination. Patient data were recorded on the case report form based on the visit.
INTRODUCTION: Chronic kidney disease (CKD) is a common risk factor for sarcopenia. However, whether sarcopenia increases the risk of CKD remains unclear. To investigate the longitudinal and causal associations between possible sarcopenia and CKD, this study was performed.
METHODS: Possible sarcopenia was defined according to the Asian Working Group for Sarcopenia in 2019. Participants aged ≥ 40 years were recruited from the baseline survey of the China Health and Retirement Longitudinal Study and followed up for four years. Binary logistic regression was used to evaluate the cross-sectional and longitudinal associations between possible sarcopenia, low muscle strength, low physical performance and CKD. Propensity score matching was used to balance the intergroup differences. Subgroup and interactive analyses were adopted to identify potential interactive effects. Mendelian Randomization analysis was used to assess the causal association between appendicular lean mass (ALM) and CKD.
RESULTS: After data cleansing, a total of 7296 participants were included in the baseline survey. In the cross-sectional analyses, the odds ratios (ORs) of prevalent CKD were 1.50 (95% CI = 1.23-1.84, p < 0.001) for possible sarcopenia, 1.37 (95% CI = 1.10-1.70, p < 0.01) for low muscle strength and 1.42 (95% CI = 1.16-1.74, p < 0.001) for low physical performance in the full models. No significant interaction effects of covariates were detected (all P for interaction > 0.05). After four years of follow-up, an increased risk of incident CKD was also observed in participants with possible sarcopenia (OR = 1.66, 95% CI = 1.13-2.44, p = 0.010) and low physical performance (OR = 1.69, 95% CI = 1.16-2.45, p = 0.006), but not in participants with low muscle strength (OR = 1.19, 95% CI = 0.75-1.88, p = 0.469). In the Mendelian Randomization analysis, the inverse variance weighted estimator showed that a 1-standard deviation increase of genetically predicted ALM was associated with a lower risk of CKD (OR = 0.92, 95% CI = 0.85-0.99, p = 0.035). All the sensitivity analyses supported the main findings.
CONCLUSIONS: Possible sarcopenia is an independent risk factor for CKD and may serve as a predictor of CKD for early identification and intervention.
PURPOSE: To obtain the subject composition free from skin irritation, effective in treating and preventing acne and having creamy foam property in using by blending an extract of a specific lamiaceous plant with an extract of bovine bone marrow. CONSTITUTION: This composition is obtained by blending (A) 0.2-3.0wt.% of an extract of Perilla frutescens Britton var. crispa (Thunb.) Decne and/or Perilla frutescens Britton var. acuta Kudo forma viridis Makino with (B) 0.2-2.0wt.% of bovine bone marrow based on total amount of the composition. Furthermore, an extract obtained by extracting dried leaf of the plant with water or an alcohol is used as the component A and an extract obtained by extracting the ground bovine backbone with hot water of an organic solvent is preferably used as the component B.
Neovascular age-related macular degeneration (nAMD) is characterized by abnormal blood vessel growth from the choroid, leading to complications and eventual blindness. Despite anti-VEGF therapy, subretinal fibrosis remains a major concern, as VEGF/VEGF receptor-2 (VEGFR2) signaling can contribute to both angiogenesis and fibrosis. For the identification of the aqueous humor proteome, we performed liquid chromatography with tandem mass spectrometry analysis. To investigate the potential therapeutic effects of targeting the VEGF signaling pathway using apatinib, a highly selective VEGFR2 tyrosine kinase inhibitor, this study employed in vitro (THP-1 conditioned media-treated ARPE-19 cells) and in vivo (laser-induced choroidal neovascularization mouse) models of nAMD. This study revealed elevated VEGFR2 protein levels in the aqueous humor of nAMD patients, suggesting a potential target to mitigate neovascularization and fibrosis in nAMD. Apatinib effectively reduced VEGFA and αSMA levels in both in vitro and in vivo models. Moreover, apatinib showed improvement in laser-induced subretinal hyper-reflective lesions. The action mechanism was linked to the inhibition of VEGFR2 activation, leading to the suppression of both angiogenesis and fibrosis through the downregulation of STAT3 phosphorylation. Therefore, the VEGFR2 signaling pathway appears to play a central role in the development of nAMD by regulating both angiogenesis and fibrosis.
The fiscal burden estimated at $164 billion annually in the US alone, with delirium often leading to significant increases in hospital length of stay. The pathophysiology of delirium is multifactorial and incompletely understood. Disruption of circadian rhythms, with subsequent impairment of alertness, and increased inflammation including neuroinflammation, is common in hospital environments, and is associated with poorer outcome, particularly in the elderly.

An intriguing new therapeutic concept currently emerging in the area of elective surgery is prehabilitation, a form of exercise training, which when pre-emptively administered in the weeks prior to admission, has the potential to improve postoperative cognitive status, mobility and recovery, thereby minimizing complications such as delirium. Our team has recently developed a novel personalized medicine intervention that uses wearable devices (smartwatches) to create an individualized exercise regimen for older adults that can facilitate prehabilitation and monitor adherence to the prehabilitation regimen while the patient is at home. In one sense, prehabilitation can be conceptualized as bouts of physical exercise performed at home prior to admission, which, when adequately timed using guidance by a wrist-worn biometric mobile device (smartwatch), augment the robustness of circadian rhythms, particularly in the elderly. This intervention has the potential to have a high impact because of its low cost, personalized nature, and ability to monitor adherence to confirm maximization of functional status prior to admission.
After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.

Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Ketoconazole and Other CYP3A4 Inhibitors

Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

Quinidine and Other CYP2D6 Inhibitors

Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with major depressive disorder, ABILIFY should be administered without dosage adjustment as specified in . DOSAGE AND ADMINISTRATION (2.3)

Carbamazepine and Other CYP3A4 Inducers

Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.
Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
Methods, systems and computer program products for health data protection. Embodiments commence upon receiving a data access request message from a participant in a health ecosystem. The data access request message comprises an indication of one or more health data sets that are held by or at least potentially of interest to the participant. System components are configured to receive the message and to identify the participant. Based on parameter values corresponding to a data protection policy of the participant, a data protection scheme is generated. The scheme includes parameter values derived from the data protection policy. The parameter values of the scheme are used to generate a variation of the health data set that is formed by applying one or more data anonymization, data obfuscation or other data protection techniques to the health data set. A balance among the parameters is calculated so as to achieve a desired outcome.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel derivatives of 3H-2,3-benzodiazepine of the general formula (I)   where values R 1 -R 7  and n are given in p. 1 of the invention claim and their physiologically tolerated salts showing AMPA-antagonistic activity also. They can be used as drug in compositions for treatments of patients with neurological and psychiatric disorders, for example, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and others. Invention describes also the method of their synthesis and pharmaceutical composition based on said. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 6 cl, 3 tbl, 53 ex
PURPOSE: The objective of this study is to identify and detail the radiologic manifestations of surgical site and disseminated Mycobacterium chimaera ( MC) infection. The aim is to facilitate early identification and diagnosis of MC, considering its indolent nature and the challenges involved in clinically and pathologically establishing the diagnosis.
PATIENTS AND METHODS: This was a retrospective cohort study reviewing computed tomography (CT), positron emission tomography (PET)/CT, and magnetic resonance imaging examinations in patients over the age of 18 years with a history of open heart surgery and a clinical or pathologic diagnosis of MC. Two radiology residents, a fellowship-trained nuclear medicine radiologist, and a fellowship-trained cardiothoracic radiologist performed consensus reads to determine the imaging findings seen in MC infection.
RESULTS: Twenty-five patients were included. Localized, surgical site infection was more common than disseminated disease. Typical CT findings included peristernal soft tissue thickening, sinus tracts often extending to the cutaneous surface, slowly enlarging fluid collections, and sternal osteolysis. PET/CT findings demonstrated hypermetabolic activity in nearly all patients localized to sites of infection. Imaging findings for disseminated infection included hepatosplenomegaly, lymphadenopathy, involvement of the central nervous system, discitis/osteomyelitis, and distant abscesses.
CONCLUSIONS: Imaging plays a vital role in suggesting possible surgical sites and disseminated MC infection acquired from open heart surgery. Radiologists must keep a high index of suspicion given the indolent nature and subtle imaging change over time. PET/CT is most useful in diagnosis and helps in differentiating between a sterile postoperative fluid collection or scarring and active MC infection and helps provide a target for debridement.
The influence of inhaled corticosteroids (ICS) on COVID-19 outcomes remains uncertain. To address this, we conducted a systematic review and meta-analysis, analyzing 30 studies, to investigate the impact of ICS on patients with COVID-19. Our study focused on various outcomes, including mortality risk, hospitalization, admission to the intensive care unit (ICU), mechanical ventilation (MV) utilization, and length of hospital stay. Additionally, we conducted a subgroup analysis to assess the effect of ICS on patients with chronic obstructive pulmonary disease (COPD) and asthma. Our findings suggest that the prior use of ICS did not lead to significant differences in mortality risk, ICU admission, hospitalization, or MV utilization between individuals who had used ICS previously and those who had not. However, in the subgroup analysis of patients with COPD, prior ICS use was associated with a lower risk of mortality compared to non-users (OR, 0.95; 95% CI, 0.90-1.00). Overall, while the use of ICS did not significantly affect COVID-19 outcomes in general, it may have beneficial effects specifically for patients with COPD. Nevertheless, more research is needed to establish a definitive conclusion on the role of ICS in COVID-19 treatment. PROSPERO registration number: CRD42021279429.
Beyond the essential role of p27Kip1 and cyclin D2 in cell cycle progression, they are also shown to confer an anti-apoptotic function in peripheral blood (PB) lymphocytes. Although the aberrant longevity and expression of p27Kip1 and cyclin D2 in leukemic cells is well documented, the exact mechanisms responsible for this phenomenon have yet to be elucidated. This study was undertaken to determine the associations between polymorphisms in the CDKN1B and CCND2 genes (encoding p27Kip1 and cyclin D2, respectively) and susceptibility to chronic lymphocytic leukemia (CLL), as well as their influence on the expression of both cell cycle regulators in PB leukemic B cells and non-malignant T cells from untreated CLL patients divided according to the genetic determinants studied. Three CDKN1B single-nucleotide polymorphisms (SNPs), rs36228499, rs34330, and rs2066827, and three CCND2 SNPs, rs3217933, rs3217901, and rs3217810, were genotyped using a real-time PCR system. The expression of p27Kip1 and cyclin D2 proteins in both leukemic B cells and non-malignant T cells was determined using flow cytometry. We found that the rs36228499A and rs34330T alleles in CDKN1B and the rs3217810T allele in the CCND2 gene were more frequent in patients and were associated with increased CLL risk. Moreover, we observed that patients possessing the CCND2rs3217901G allele had lower susceptibility to CLL (most pronounced in the AG genotype). We also noticed that the presence of the CDKN1Brs36228499CC, CDKN1Brs34330CC, CDKN1Brs2066827TT, and CCND2rs3217901AG genotypes shortened the time to CLL progression. Statistically significant functional relationships were limited to T cells and assigned to CDKN1B polymorphic variants; carriers of the polymorphisms rs34330CC and rs36228499CC (determining the aggressive course of CLL) expressed a decrease in p27Kip1 and cyclin D2 levels, respectively. We indicate for the first time that genetic variants at the CDKN1B and CCND2 loci may be considered as a potentially low-penetrating risk factor for CLL and determining the clinical outcome.
Fluoroquinolones, including moxifloxacin hydrochloride, may cause central nervous system (CNS) events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia. [See Adverse Reactions (6.2, 6.4).] 

Convulsions and increased intracranial pressure (including pseudotumor cerebri) have been reported in patients receiving fluoroquinolones. Fluoroquinolones may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving moxifloxacin hydrochloride, the drug should be discontinued and appropriate measures instituted. As with all fluoroquinolones, moxifloxacin hydrochloride should be used with caution in patients with known or suspected CNS disorders (for example, severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold. [See Drug Interactions (7.4) Adverse Reactions (6.2, 6.4) and Patient Counseling Information (17).]
CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
Medical imaging plays a huge role in clinical diagnosis. At present, the commonly used imaging methods for neonatal brain imaging include ultrasound imaging, magnetic resonance imaging, and CT. Due to the imaging scale, speed, and radiation limitation, large imaging devices such as CT and magnetic resonance imaging usually have limitations in the early screening and diagnosis of neonatal brain lesions. With the advantages of flexibility and convenience, ultrasound has become a common imaging method for neonatal brain organs. However, conventional ultrasound imaging usually only provides structure-related information, and it is difficult to reveal the physiological characteristics of the lesions. Therefore, this project aims to develop a high-speed multi-modal photoacoustic/ultrasound functional imaging system to provide structural and functional information of tissues and organs, thereby improving the accuracy of early screening and diagnosis of neonatal brain lesions. The imaging technique is completely noninvasive and does not use any ionizing radiation or contrast media. A product that uses the same technology as this imaging device has been approved by the FDA and entered the clinic in the United States.

The imaging device consists of two imaging modalities, photoacoustic imaging and ultrasound imaging. Photoacoustic imaging (PAI) can be used to image the optical absorption characteristics of human tissues by safely irradiating the human body with near-infrared light (complying with international safety standards) to produce a short time temperature rise (less than 0.1 degrees Celsius), resulting in a weak ultrasound signal. The ultrasonic imaging principle of the device is the same as that of clinical B-ultrasound, which uses ultrasound to safely irradiate the body (obeying international safety standards) and obtain reflected signals. This project is supported by the Young Scientist Project of Diagnosis and Treatment Equipment of the Key Research and Development Program of the Ministry of Science and Technology, jointly applied by the research group of Teacher Lin Li from Zhejiang University and the research group of Huang Pin from the Second Affiliated Hospital of Zhejiang University School of Medicine. This project aims to develop a new generation of multimodal photoacoustic/ultrasound functional imaging equipment to reveal the physiological characteristics and structural details of neonatal brain lesions. And traditional medical imaging methods form advantages and information complementary.